Dalmevin 50 mg comprimate Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

dalmevin 50 mg comprimate

medochemie ltd - vildagliptinum - comprimate - 50 mg

ASPACARDIN 39 mg/12 mg România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

aspacardin 39 mg/12 mg

terapia s.a. - romania - combinatii - compr. - 39mg/12mg - potasium (kalium) medicamente cu potasiu

ASPAMED 39 mg/12 mg România - română - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

aspamed 39 mg/12 mg

arena group s.a. - romania - combinatii - compr. - 39mg/12mg - potasium (kalium) medicamente cu potasiu

Janumet comprimate filmate 1000 mg + 50 mg Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janumet comprimate filmate 1000 mg + 50 mg

schering-plough central east ag - metforminum + sitagliptinum - comprimate filmate - 1000 mg + 50 mg

Janumet comprimate filmate 500 mg + 50 mg Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janumet comprimate filmate 500 mg + 50 mg

schering-plough central east ag - metforminum + sitagliptinum - comprimate filmate - 500 mg + 50 mg

Janumet comprimate filmate 850 mg + 50 mg Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

janumet comprimate filmate 850 mg + 50 mg

schering-plough central east ag - metforminum + sitagliptinum - comprimate filmate - 850 mg + 50 mg

Sitagliptin SUN Uniunea Europeană - română - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Sitagliptin Accord Uniunea Europeană - română - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Glucophage XR comprimate cu eliberare prelungita 500 mg Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glucophage xr comprimate cu eliberare prelungita 500 mg

merck sante s.a.s. - metforminum - comprimate cu eliberare prelungita - 500 mg

Humulin M suspensie injectabila in cartus 100 UI/ml Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

humulin m suspensie injectabila in cartus 100 ui/ml

lilly france s.a.s. - insulinum umane - suspensie injectabila in cartus - 100 ui/ml